Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials.
J M VersluisA M MenziesK SikorskaE A RozemanR P M SawW J van HoudtH ErikssonW M C KlopS Ch'ngJ V van ThienenH MalloM GonzalezA Torres AcostaL G Grijpink-OngeringA van der WalA BruiningB A van de WielR A ScolyerJ B A G HaanenT N SchumacherA C J van AkkooiG V LongC U BlankPublished in: Annals of oncology : official journal of the European Society for Medical Oncology (2023)
Updated data confirm the high survival rates after neoadjuvant combination checkpoint inhibition in macroscopic stage III melanoma, especially for patients with a pathologic response. Pathologic response is the strongest surrogate marker for long-term outcome.